OSST should be closely monitored for rejection

Article

Ocular surface stem cell transplantation (OSST) patients should be closely monitored for rejection and compliance with immunosuppression.

Ocular surface stem cell transplantation (OSST) patients should be closely monitored for rejection and compliance with immunosuppression, claims a paper in the journal Cornea.

Dr A.Y. Ang et al., Cincinnati Eye Institute, Cincinnati, Ohio, USA, conducted a chart review of 222 eyes of 158 patients who underwent OSST at a single institution between 1998 and 2010. The group collected data on patient demographics, type of OSST procedure, duration of immunosuppression and rejection characteristics. The primary outcome measures were ocular surface stability and improvement in BCVA.

The most common indications for OSST were aniridia in 46.4% of patients, chemical/thermal injury in 22.1% and Stevens-Johnson syndrome in 12.2%. The most frequent procedures performed were keratolimbal allograft (KLAL) alone in 80.6% of patients and combined living-related conjunctival allograft (lr-CLAL)-KLAL in 11.3%.

Severe rejection was seen in 43 eyes, while low-grade rejection occurred in 26 eyes. At the final follow-up, 36.6% of eyes in the rejection group presented with a stable ocular surface, compared with 71.9% of eyes in the non-rejection group. Younger age, KLAL alone and noncompliance with immunosuppression were all factors that played a significant part in increasing the risk of rejection.

Please click here to read the abstract.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.